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Although the evidence is not consistent, epidemiologic studies have suggested that
taller adult height may be associated with an increased risk of some non-Hodgkin
lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how
these genetic factors may contribute to NHL risk is unknown. We investigated the
relationship between genetic determinants of height and NHL risk using data from eight
genome-wide association studies (GWAS) comprising 10,629 NHL cases, including
3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100
chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases,
and 9,505 controls of European ancestry. We evaluated genetically predicted height by
constructing polygenic risk scores using 833 height-associated SNPs. We used logistic
regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for association
between genetically determined height and the risk of four NHL subtypes in each GWAS
and then used fixed-effect meta-analysis to combine subtype results across studies. We
found suggestive evidence between taller genetically determined height and increased
CLL risk (OR = 1.08, 95% CI = 1.00–1.17, p = 0.049), which was slightly stronger
among women (OR = 1.15, 95% CI: 1.01–1.31, p = 0.036). No significant associations
were observed with DLBCL, FL, or MZL. Our findings suggest that there may be some
shared genetic factors between CLL and height, but other endogenous or environmental
factors may underlie reported epidemiologic height associations with other subtypes.
Keywords: non-Hodgkin lymphoma, height, genetics, chronic lymphocytic leukemia, diffuse large B-cell
lymphoma, follicular lymphoma, marginal zone lymphoma, polygenic risk score
INTRODUCTION
In epidemiologic studies, taller adult height has been associated
with an increased risk of several subtypes of non-Hodgkin
lymphoma (NHL) (1); however, the results have not been
consistent across studies for common subtypes, such as diffuse
large B-cell lymphoma (DLBCL), follicular lymphoma (FL),
and chronic lymphocytic leukemia/small cell lymphoma (CLL)
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(2–13). Taller height has also been positively associated with other
cancers in both epidemiologic and Mendelian randomization
studies (14–16). The underlying reason or biological mechanism
for these associations is not understood. Adult attained height
is not thought to be causally related to cancer, but instead
thought to be a marker of other biological influences, including
hormonal and growth factors, cellular divisions, and nutrition
during formative years, that may contribute to cancer risk over
the life course of an individual.
The reported positive associations between height and
multiple subtypes of NHL suggest the existence of common
biological pathways, possibly mediated by genetic factors. Height
is a highly polygenic trait and estimated to be 70–80% heritable
based on twin studies (17–19). Genome-wide association
studies (GWAS) have identified hundreds of common variants
associated with height to date, which explain approximately 16%
of the variance of height (20), with additional rare variants also
contributing to its variance (21). A deeper understanding of how
height is associated with NHL risk may provide insight into
underlying biological mechanisms leading to lymphoma.
In this study, we used previously established height-related
genetic variants to construct polygenic risk scores (PRS) for
height in order to examine the associations between genetically-
inferred height and the risk of four common NHL subtypes:
DLBCL, FL, CLL, and MZL.
METHODS
We used data from eight GWAS of NHL subtypes in populations
of European ancestry (Supplementary Table 1), the details of
which have been reported previous for DLBCL (22), FL (23),
CLL (24), and MZL (25). The largest GWAS, the National
Cancer Institute (NCI) NHL GWAS, consisted of cases and
controls of European ancestry from 22 studies of NHL,
including nine prospective cohort studies, eight population-
based case-control studies, and five hospital or clinic-based case-
control or case-series studies. The other seven GWAS consisted
of two population-based case-control studies, one combined
clinic- and population-based case-control study, one clinic-
based case-control study with additional registry cases, one case
series with population-based controls, one randomized clinical
trial with population-based controls, and one case-control
study enriched for familial cases (Supplementary Table 1). The
29 epidemiologic studies contributing to these GWAS were
conducted in the North America, Australia, and Europe. In total,
genotype data were available for 3,100 CLL cases, 3,857 DLBCL
cases, 2,847 FL cases, and 825 MZL cases, and 9,505 controls. All
studies obtained informed consent from participants and were
approved by their appropriate Institutional Review Boards.
Genotyping was performed on commercially available
Illumina and Affymetrix platforms (Supplementary Table 1).
Standard quality control and filtering were applied to each
GWAS, and each GWAS was imputed separately. Imputation
was performed using IMPUTE2 (26) and the 1,000 Genomes
Project version 2, February 2012 release (27) as the reference
panel. As reported previously (22–25), quantile-quantile plots of
the results showed no substantial evidence of inflation.
Previous studies have reported 848 independent, autosomal
SNPs to be associated with height in primarily in European
populations (20, 21). Wood et al. (20) identified 697 independent
SNPs associated with height based on an approximate conditional
analysis, taking the linkage disequilibrium among SNPs into
account. Marouli et al. (21) identified an additional 113 novel
autosomal loci, which were > 1Mb from the loci reported by
Wood et al. and 38 SNPs near established loci that were shown to
be independent of previously reported SNPs based on conditional
analyses. We constructed weighted polygenic risk scores (PRS)
using 833 of these previously reported SNPs, which were available
in our datasets with information scores > 0.3 and p-values for
Hardy-Weinberg equilibrium >1 × 10−5. To generate the PRS,
the height-increasing allelic dosage for each SNP was multiplied
by the reported meta-analysis beta coefficient (20, 21), as shown
below, where wj is the weight or beta coefficient for the jth SNP
derived from the literature and xij is the allelic dosage of the
jth SNP.
PRSi =
k∑
j = 1
wjxij
As previous studies have shown etiologic heterogeneity among
NHL subtypes (1), we analyzed each NHL subtype separately.
For each GWAS, we performed logistic regression with the
PRS, which was normally distributed, modeled as a continuous
variable. Models were adjusted for sex, age, and statistically
significant principal components for population stratification (p
< 0.05) at the GWAS level. Since all controls in the UCSF1/NHS
GWAS were female, models for this GWAS were adjusted for
age and significant principal components of ancestry only. In a
sensitivity analysis, we also adjusted for genetically determined
body mass index (BMI), using previously established loci. The
regression analyses were performed in R using the glm function.
For each NHL subtype, GWAS-specific risk estimates were
pooled using fixed-effect meta-analysis (28). Only one GWAS
contributed to MZL, so no meta-analysis was performed for
MZL. Between-GWAS heterogeneity was evaluated by the
Cochran’s Q test and quantified using the I2 metric (29). Meta-
analyses were conducted using the package metan in Stata v15
(StataCorp, College Station, TX). The UCSF1/NHS GWAS was
excluded from the sex-specific meta-analysis of FL because all
controls were female. Between-sex heterogeneity was evaluated
by performing a fixed-effect meta-analysis to obtain the p-value
from the Cochran’s Q-test and I2.
RESULTS
We found suggestive evidence for an association between taller
genetically determined height and risk of CLL (OR = 1.08,
95% CI 1.00–1.17, p = 0.049), with the PRS modeled as a
continuous variable (Table 1). Additional adjustment for BMI
did not substantially alter the association (OR = 1.07, 95%
CI 0.99–1.16). This association was stronger among females
(OR = 1.15, 95% CI 1.01–1.31, p = 0.04) than among males
(OR = 1.06, 95% CI 0.96–1.18, p = 0.26), but the between-sex
heterogeneity was not statistically significant (p = 0.34). No
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TABLE 1 | Association between genetically predicted height and the risk of NHL
by subtype.
No. cases/ No.
controls
OR 95% CI P I2* (%) P*het
CLL
Men + Women 3100/7666 1.08 1.00–1.17 0.049 0.0 0.690
Men 1794/5370 1.06 0.96–1.18 0.264 0.0 0.444
Women 1306/2296 1.15 1.01–1.31 0.036 0.0 0.732
DLBCL
Men + Women 3587/7666 1.05 0.97–1.14 0.209 27.2 0.249
Men 1968/5260 1.02 0.92–1.13 0.731 2.1 0.382
Women 1889/2406 1.08 0.96–1.22 0.205 0.0 0.539
FL
Men + Women 2847/8107 1.06 0.97–1.16 0.230 57.5 0.070
Men† 1276/5208 1.03 0.91–1.17 0.667 0.0 0.515
Women† 1452/2550 1.05 0.92–1.20 0.470 67.2 0.048
MZL
Men + Women 825/6221 1.10 0.95–1.28 0.201
Men 334/4527 1.19 0.96–1.49 0.116
Women 491/1694 1.00 0.82–1.23 0.967
*Heterogeneity among GWAS. Only one GWAS contributed to MZL, so heterogeneity not
evaluated for that subtype.
†
Sex-specific FL analysis excludes UCSF1/NHS study.
significant heterogeneity among studies was observed for CLL
among males and females combined (I2 = 0%, phet = 0.69,
Supplementary Table 2).
No association was observed between genetically predicted
height and the risk of DLBCL (OR = 1.05, 95% CI 0.97–1.14),
FL (OR = 1.06, 95% CI 0.97–1.16), or MZL (OR = 1.10, 95%
CI 0.95–1.28) (Table 1). Adjustment for BMI did not alter these
results (data not shown). For FL, there was some heterogeneity
in the GWAS-specific risk estimates (I2 = 57.5%, phet = 0.07,
Supplementary Table 2), attributable primarily to the inclusion
of the SCALE study. Removal of SCALE from the meta-analysis
for FL risk slightly strengthened the combined association, but
the resulting association did not reach statistical significance (OR
= 1.09, 95% CI 0.99–1.20, p= 0.08). With regards to sex-specific
analyses for these three subtypes, no significant associations were
seen among men or women, with risk estimates similar to those
observed for both sexes combined.
DISCUSSION
In this first examination of genetically inferred height and NHL
risk, we observed a borderline positive association between
genetically inferred taller height and the risk of CLL. This
finding is consistent with observations from epidemiologic
studies examining height and CLL risk, which generally have
reported positive or insignificant associations (2, 3, 5, 11). The
prospective UK Million Women Study, with 920 CLL cases,
found an increased risk of CLL with increasing height (2).
Although the Netherlands Cohort Study observed an overall
association between taller adult height and risk of NHL overall,
it did not observe a significantly elevated risk of CLL with 165
CLL cases (5). A previous pooled analysis within the InterLymph
Consortium found an overall positive association between
reported height and risk of CLL with a modest magnitude of
association (OR per 10-cm increase = 1.10, 95% CI = 1.02–
1.19) (11), which is comparable to the association with a one-
unit increase in the PRS from the present study, but without
a suggestion of heterogeneity by sex. Collectively, the present
and published data provide evidence for a positive association
between adult height and risk of CLL, although additional studies
are needed to clarify possible sex differences.
No evidence of association was observed between genetically
determined height and the risk of DLBCL, FL, nor MZL.
Although the findings are not consistent (3, 8), some
epidemiologic studies have reported positive findings for
common NHL subtypes and height (2, 30). The UK Million
Women Study reported a positive association with height for
FL, DLBCL, and NHL overall (2). A large pooled analysis within
the InterLymph Consortium found that greater adult height
was positively associated FL for males, but not females (12).
Consistent with our results, no significant associations were
reported between adult height and MZL or DLBCL in the
InterLymph pooled analysis (13, 31); however, an increased risk
of DLBCL was observed for both sexes combined comparing
the highest with the lowest quartile of usual adult height in a
minimally adjusted model (31). It should be noted that some of
the cases and controls included in our analysis were also included
in the InterLymph pooled analyses of reported height and NHL
risk (32); however, our study included 2,550 cases and 4,330
controls from prospective studies as well, which were not part of
the pooled InterLymph analyses (Supplementary Table 1).
Despite the suggestive associations in the literature for self-
reported or measured height and FL and DLBCL risk, there are
several possible reasons why our study of genetically determined
adult height did not identify statistically significant associations.
A recent methodologic paper on the use of polygenic risk scores
demonstrated that null results are often explained by inadequate
sample size (33). Even though our study utilized data from the
largest GWAS of NHL to date, it is a possible that our study was
underpowered to detect an association for these NHL subtypes.
In addition, it is possible that the genetic component of height
that is pleiotropically related to risk of these NHL subtypes is
not well-captured by the current set of height-associated variants.
The PRS for height constructed for the present analyses accounts
for <20% of the heritable component of adult height (20, 21). A
PRS incorporating a larger fraction of the heritable component of
adult height would provide a more precise measure of the genetic
contribution to height and allow for a better assessment of the
association with NHL risk. As more of the genetic component of
height becomes identified, it may be possible to create a better
PRS that accounts for a larger percentage of height variation.
Finally, it is also possible that it is the non-genetic component
of height, such as childhood nutrition, or a factor correlated
with height that is responsible for the reported epidemiologic
associations between adult stature and risk of NHL.
Among the noteworthy limitations of our study is the fact
that our participants were from populations of European descent,
limiting the generalizability of results. However, this restriction
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to Europeans also has the benefit of minimizing bias from
population stratification, which is an important concern with
studies of height. We did not adjust for multiple testing, because
previous studies have shown individual NHL subtypes to have
distinct etiologies (1). However, it is possible that the finding we
observed with CLL may be a false-positive result, and additional
studies are needed to replicate our findings. We were unable
to perform a true Mendelian randomization analysis due to
lack of data on height from many studies, but we were able to
combine multiple GWAS of NHL by meta-analysis to achieve
sample sizes of several thousand cases for three of the four
subtypes. This approach further enabled a direct assessment of
between-study and between-sex heterogeneity of the observed
associations. Future studies with even larger sample sizes may be
able to evaluate the shared genetic correlation with height using
cross-trait LD Score regression.
In conclusion, we present the first polygenic risk score analysis
examining the genetic contribution of attained adult height on
the risk for the four most common NHL subtypes. Although we
did not observe statistically significant associations with DLBCL,
FL, or MZL, we observed evidence of a positive association
between genetically-inferred height and CLL risk, lending more
support to previous observational studies. Additional studies
are warranted to explore the association between genetically-
inferred height and risk of other NHL subtypes, particularly
those that have been reported to be associated with self-
reported or measured height in epidemiologic studies (34, 35).
Additional insight could be gained from studies that explore
the relationship between environmental or endogenous factors
that may be correlated with or determinants of height and
NHL risk. As more knowledge is gained about the genetic
architecture and determinants of height, a more informative PRS
can be constructed to represent a larger fraction of the heritable
component of adult height and underlying biological pathways.
A re-examination of the associations of NHL subtypes with
genetically-inferred height may be merited in the future as our
understanding of height and its underlying biology grows.
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